Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-04-17
DOI
10.1093/neuonc/noz073
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
- (2018) Raelene Endersby et al. NEOPLASIA
- Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
- (2018) Martin J. Van Den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma
- (2017) S A Greenall et al. Oncogenesis
- Incomplete target neutralization by the anti-cancer antibody rilotumumab
- (2016) Sameer A. Greenall et al. mAbs
- A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
- (2015) Manfred Westphal et al. EUROPEAN JOURNAL OF CANCER
- Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells
- (2015) Jake Chng et al. mAbs
- EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications
- (2015) S A Greenall et al. ONCOGENE
- The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases
- (2015) Vinochani Pillay et al. NEOPLASIA
- Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
- (2012) SHASHA LV et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation
- (2011) Mariusz P. Madej et al. BIOTECHNOLOGY AND BIOENGINEERING
- Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib--A Phase II Trial
- (2011) M. E. Hegi et al. MOLECULAR CANCER THERAPEUTICS
- Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation
- (2011) Susie I. Ymer et al. Cancers
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- (2009) B. Neyns et al. ANNALS OF ONCOLOGY
- Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells
- (2009) Barry Jutten et al. RADIOTHERAPY AND ONCOLOGY
- EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma
- (2009) Q.-W. Fan et al. Science Signaling
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now